Biomarkers /
BRCA2
Back to Biomarkers List
Overview
Breast cancer 2, early onset (BRCA2) is a gene that encodes a protein that functions in maintaining genomic stability and as a tumor suppressor. Missense mutations, nonsense mutations, silent mutations, whole gene deletions, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
BRCA2 is altered in 5.02% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, prostate adenocarcinoma, and endometrial endometrioid adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in BRCA2 are BRCA2 Mutation (3.77%), BRCA2 Nonsense (0.48%), BRCA2 Loss (0.26%), BRCA2 Amplification (0.25%), and BRCA2 Fusion (0.08%) [3].
Biomarker-Directed Therapies
BRCA2 is a predictive biomarker for use of olaparib, rucaparib, bevacizumab, niraparib, and talazoparib in patients.
Fallopian tube carcinoma, malignant ovarian neoplasm, primary peritoneal carcinoma, breast carcinoma, and prostate carcinoma have the most therapies with BRCA2 as a predictive biomarker.
Of the therapies with BRCA2 as a predictive biomarker, 5 are FDA-approved in at least one clinical setting and 4 have NCCN guidelines in at least one clinical setting.
BRCA2 Mutation, BRCA2 Loss, BRCA2 Mutation (germline), and BRCA2 Loss (germline) are the top alterations on BRCA2 targeted by therapies [4].
Niraparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens. |
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious mutations in patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens. |
Olaparib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for BRCA1/2 deleterious germline mutations in patients with metastatic, HER2-negative breast cancer. NCCN supports use for any HER2 status. |
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN) | |
| Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN), Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for patients with advanced ovarian cancer (1) with BRCA1/2 deleterious germline mutations who have been treated with three or more prior lines of chemotherapy, and (2) for maintenance treatment with BRCA1/2 deleterious germline or somatic mutations with complete or partial response to first-line chemotherapy. |
Malignant Peritoneal Neoplasm -
Pancreatic Adenocarcinoma -
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA, NCCN) | |
| Note: Indicated for maintenance treatment of patients with advanced fallopian tube or primary peritoneal cancer with BRCA1/2 deleterious germline or somatic mutations and complete or partial response to first-line chemotherapy. |
Prostate Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
ATM Mutation, BRCA1 Mutation, BRCA2 Mutation, FANCL Mutation, PALB2 Mutation, ATM Loss, BARD1 Loss, BARD1 Mutation, BRCA1 Loss, BRCA2 Loss, BRIP1 Loss, BRIP1 Mutation, CDK12 Loss, CDK12 Mutation, CHEK1 Loss, CHEK1 Mutation, CHEK2 Loss, CHEK2 Mutation, FANCL Loss, PALB2 Loss, RAD51B Loss, RAD51B Mutation, RAD51C Loss, RAD51C Mutation, RAD51D Loss, RAD51D Mutation, RAD54L Loss, RAD54L Mutation |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Approved for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone. |
Rucaparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious germline or somatic mutations in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious germline or somatic mutations in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. |
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN), Recurrent (FDA, NCCN) | |
| Note: Indicated for BRCA1/2 deleterious germline or somatic mutations in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. |
Prostate Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for deleterious BRCA mutations (germline and/or somatic) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. |
Talazoparib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. NCCN supports use for any HER2 status. |
Bevacizumab + Olaparib +
Fallopian Tube Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA) | |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Malignant Ovarian Neoplasm -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA) | |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Primary Peritoneal Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Maintenance therapy (FDA) | |
| Note: Approved as a maintenance regimen for advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency and are responding to first-line platinum-based chemotherapy. |
Clinical Trials
BRCA2 status serves as an inclusion eligibility criteria in 201 clinical trials, of which 161 are open and 40 are closed. Of the trials that contain BRCA2 status as an inclusion criterion, 3 are early phase 1 (3 open), 36 are phase 1 (26 open), 24 are phase 1/phase 2 (18 open), 110 are phase 2 (89 open), 3 are phase 2/phase 3 (3 open), 21 are phase 3 (19 open), 2 are phase 4 (2 open), and 2 are no phase specified (1 open).
Trials with BRCA2 status in the inclusion eligibility criteria most commonly target breast carcinoma, malignant solid tumor, ovarian carcinoma, primary peritoneal carcinoma, and fallopian tube carcinoma [4].
The most frequent alterations to serve as inclusion eligibility criteria are BRCA2 Loss and BRCA2 Mutation [4].
Olaparib, talazoparib, niraparib, rucaparib, and carboplatin are the most frequent therapies in trials with BRCA2 as an inclusion criteria [4].
Significance of BRCA2 in Diseases
Breast Carcinoma +
BRCA2 is altered in 4.48% of breast carcinoma patients [3].
BRCA2 is an inclusion criterion in 70 clinical trials for breast carcinoma, of which 56 are open and 14 are closed. Of the trials that contain BRCA2 status and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 16 are phase 1 (10 open), 10 are phase 1/phase 2 (8 open), 32 are phase 2 (27 open), 1 is phase 2/phase 3 (1 open), 9 are phase 3 (8 open), and 1 is phase 4 (1 open) [4].
Olaparib and talazoparib have evidence of efficacy in patients with BRCA2 mutation in breast carcinoma [4].
Primary Peritoneal Carcinoma +
BRCA2 is altered in 13.64% of primary peritoneal carcinoma patients [3].
BRCA2 is an inclusion criterion in 31 clinical trials for primary peritoneal carcinoma, of which 24 are open and 7 are closed. Of the trials that contain BRCA2 status and primary peritoneal carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (6 open), 1 is phase 2/phase 3 (1 open), 5 are phase 3 (4 open), and 2 are phase 4 (2 open) [4].
Bevacizumab, olaparib, niraparib, and rucaparib have evidence of efficacy in patients with BRCA2 mutation in primary peritoneal carcinoma [4].
Fallopian Tube Carcinoma +
BRCA2 is altered in 1.82% of fallopian tube carcinoma patients [3].
BRCA2 is an inclusion criterion in 29 clinical trials for fallopian tube carcinoma, of which 22 are open and 7 are closed. Of the trials that contain BRCA2 status and fallopian tube carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 10 are phase 2 (6 open), 5 are phase 3 (4 open), and 2 are phase 4 (2 open) [4].
Olaparib, bevacizumab, niraparib, and rucaparib have evidence of efficacy in patients with BRCA2 mutation in fallopian tube carcinoma [4].
Prostate Carcinoma +
BRCA2 is altered in 6.61% of prostate carcinoma patients [3].
BRCA2 is an inclusion criterion in 25 clinical trials for prostate carcinoma, of which 21 are open and 4 are closed. Of the trials that contain BRCA2 status and prostate carcinoma as inclusion criteria, 5 are phase 1 (4 open), 3 are phase 1/phase 2 (2 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [4].
Olaparib and rucaparib have evidence of efficacy in patients with BRCA2 mutation in prostate carcinoma [4].
Pancreatic Adenocarcinoma +
BRCA2 is altered in 5.19% of pancreatic adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 10 clinical trials for pancreatic adenocarcinoma, of which 9 are open and 1 is closed. Of the trials that contain BRCA2 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 7 are phase 2 (7 open), and 1 is phase 3 (1 open) [4].
Olaparib has evidence of efficacy in patients with BRCA2 mutation in pancreatic adenocarcinoma [4].
Malignant Peritoneal Neoplasm +
BRCA2 is altered in 13.64% of malignant peritoneal neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant peritoneal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and malignant peritoneal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Olaparib has evidence of efficacy in patients with BRCA2 mutation in malignant peritoneal neoplasm [4].
Malignant Ovarian Neoplasm +
BRCA2 is altered in 6.02% of malignant ovarian neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and malignant ovarian neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].
Olaparib, bevacizumab, niraparib, and rucaparib have evidence of efficacy in patients with BRCA2 mutation in malignant ovarian neoplasm [4].
Malignant Solid Tumor +
BRCA2 is altered in 5.45% of malignant solid tumor patients [3].
BRCA2 is an inclusion criterion in 54 clinical trials for malignant solid tumor, of which 43 are open and 11 are closed. Of the trials that contain BRCA2 status and malignant solid tumor as inclusion criteria, 24 are phase 1 (18 open), 12 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [4].
Ovarian Carcinoma +
BRCA2 is altered in 6.25% of ovarian carcinoma patients [3].
BRCA2 is an inclusion criterion in 40 clinical trials for ovarian carcinoma, of which 32 are open and 8 are closed. Of the trials that contain BRCA2 status and ovarian carcinoma as inclusion criteria, 3 are early phase 1 (3 open), 10 are phase 1 (7 open), 8 are phase 1/phase 2 (7 open), 14 are phase 2 (11 open), 4 are phase 3 (3 open), and 1 is phase 4 (1 open) [4].
Prostate Adenocarcinoma +
BRCA2 is altered in 6.49% of prostate adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 20 clinical trials for prostate adenocarcinoma, of which 18 are open and 2 are closed. Of the trials that contain BRCA2 status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [4].
High Grade Ovarian Serous Adenocarcinoma +
BRCA2 is altered in 6.76% of high grade ovarian serous adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 12 clinical trials for high grade ovarian serous adenocarcinoma, of which 7 are open and 5 are closed. Of the trials that contain BRCA2 status and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 6 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].
Non-Small Cell Lung Carcinoma +
BRCA2 is altered in 4.54% of non-small cell lung carcinoma patients [3].
BRCA2 is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 8 are open and 2 are closed. Of the trials that contain BRCA2 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [4].
Pancreatic Carcinoma +
BRCA2 is altered in 5.08% of pancreatic carcinoma patients [3].
BRCA2 is an inclusion criterion in 10 clinical trials for pancreatic carcinoma, of which 9 are open and 1 is closed. Of the trials that contain BRCA2 status and pancreatic carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [4].
Endometrial Carcinoma +
BRCA2 is altered in 9.16% of endometrial carcinoma patients [3].
BRCA2 is an inclusion criterion in 9 clinical trials for endometrial carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA2 status and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 2 are phase 3 (2 open) [4].
High Grade Fallopian Tube Serous Adenocarcinoma +
BRCA2 is altered in 1.82% of high grade fallopian tube serous adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 9 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 6 are open and 3 are closed. Of the trials that contain BRCA2 status and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 4 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].
Adenocarcinoma Of The Gastroesophageal Junction +
BRCA2 is altered in 4.89% of adenocarcinoma of the gastroesophageal junction patients [3].
BRCA2 is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain BRCA2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].
Fallopian Tube Endometrioid Adenocarcinoma +
BRCA2 is an inclusion criterion in 7 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 4 are open and 3 are closed. Of the trials that contain BRCA2 status and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Urothelial Carcinoma +
BRCA2 is altered in 8.2% of urothelial carcinoma patients [3].
BRCA2 is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA2 status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].
Primary Peritoneal Serous Adenocarcinoma +
BRCA2 is altered in 13.64% of primary peritoneal serous adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 6 clinical trials for primary peritoneal serous adenocarcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA2 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Small Cell Lung Carcinoma +
BRCA2 is altered in 4.69% of small cell lung carcinoma patients [3].
BRCA2 is an inclusion criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA2 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [4].
Hereditary Breast And Ovarian Cancer Syndrome +
BRCA2 is an inclusion criterion in 6 clinical trials for hereditary breast and ovarian cancer syndrome, of which 3 are open and 3 are closed. Of the trials that contain BRCA2 status and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 2 (1 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Colorectal Carcinoma +
BRCA2 is altered in 8.41% of colorectal carcinoma patients [3].
BRCA2 is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRCA2 status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].
Gastric Adenocarcinoma +
BRCA2 is altered in 6.39% of gastric adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRCA2 status and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [4].
Gastric Carcinoma +
BRCA2 is altered in 6.33% of gastric carcinoma patients [3].
BRCA2 is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA2 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].
Head And Neck Carcinoma +
BRCA2 is altered in 4.85% of head and neck carcinoma patients [3].
BRCA2 is an inclusion criterion in 5 clinical trials for head and neck carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA2 status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].
Ovarian Endometrioid Adenocarcinoma +
BRCA2 is altered in 6.15% of ovarian endometrioid adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 4 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 2 are closed. Of the trials that contain BRCA2 status and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (1 open) [4].
Cervical Carcinoma +
BRCA2 is altered in 2.89% of cervical carcinoma patients [3].
BRCA2 is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Non-Hodgkin Lymphoma +
BRCA2 is altered in 2.69% of non-hodgkin lymphoma patients [3].
BRCA2 is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [4].
Soft Tissue Sarcoma +
BRCA2 is altered in 2.65% of soft tissue sarcoma patients [3].
BRCA2 is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].
Breast Lobular Carcinoma In Situ +
BRCA2 is an inclusion criterion in 4 clinical trials for breast lobular carcinoma in situ, of which 2 are open and 2 are closed. Of the trials that contain BRCA2 status and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Primary Peritoneal Endometrioid Adenocarcinoma +
BRCA2 is an inclusion criterion in 4 clinical trials for primary peritoneal endometrioid adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA2 status and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].
Bladder Carcinoma +
BRCA2 is altered in 8.33% of bladder carcinoma patients [3].
BRCA2 is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].
Head And Neck Squamous Cell Carcinoma +
BRCA2 is altered in 6.06% of head and neck squamous cell carcinoma patients [3].
BRCA2 is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [4].
Ductal Carcinoma In Situ +
BRCA2 is altered in 4.35% of ductal carcinoma in situ patients [3].
BRCA2 is an inclusion criterion in 3 clinical trials for ductal carcinoma in situ, of which 1 is open and 2 are closed. Of the trials that contain BRCA2 status and ductal carcinoma in situ as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [4].
Malignant Ovarian Epithelial Tumor +
BRCA2 is altered in 6.12% of malignant ovarian epithelial tumor patients [3].
BRCA2 is an inclusion criterion in 3 clinical trials for malignant ovarian epithelial tumor, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open), 1 is phase 2 (0 open), and 1 is phase 4 (1 open) [4].
Pancreatic Ductal Adenocarcinoma +
BRCA2 is altered in 2.94% of pancreatic ductal adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (1 open) [4].
Invasive Breast Carcinoma +
BRCA2 is altered in 4.47% of invasive breast carcinoma patients [3].
BRCA2 is an inclusion criterion in 3 clinical trials for invasive breast carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 status and invasive breast carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is no phase specified (0 open) [4].
Ovarian Undifferentiated Carcinoma +
BRCA2 is an inclusion criterion in 3 clinical trials for ovarian undifferentiated carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].
Bladder Urothelial Carcinoma +
BRCA2 is altered in 8.26% of bladder urothelial carcinoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Squamous Cell Lung Carcinoma +
BRCA2 is altered in 5.63% of squamous cell lung carcinoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].
Ovarian Endometrioid Tumor +
BRCA2 is altered in 6.12% of ovarian endometrioid tumor patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for ovarian endometrioid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian endometrioid tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) and 1 is phase 3 (1 open) [4].
Malignant Central Nervous System Neoplasm +
BRCA2 is altered in 4.26% of malignant central nervous system neoplasm patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Malignant Ovarian Serous Tumor +
BRCA2 is altered in 6.27% of malignant ovarian serous tumor patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for malignant ovarian serous tumor, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 status and malignant ovarian serous tumor as inclusion criteria, 1 is phase 2 (0 open) and 1 is phase 2/phase 3 (1 open) [4].
Esophageal Carcinoma +
BRCA2 is altered in 5.35% of esophageal carcinoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].
Clear Cell Renal Cell Carcinoma +
BRCA2 is altered in 3.45% of clear cell renal cell carcinoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].
Esophageal Adenocarcinoma +
BRCA2 is altered in 5.12% of esophageal adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Ewing Sarcoma +
BRCA2 is altered in 1.91% of Ewing sarcoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Low Grade Ovarian Serous Adenocarcinoma +
BRCA2 is altered in 1.59% of low grade ovarian serous adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for low grade ovarian serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Ovarian Mixed Epithelial Tumor +
BRCA2 is altered in 2.86% of ovarian mixed epithelial tumor patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for ovarian mixed epithelial tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian mixed epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (1 open) [4].
Gastrointestinal Stromal Tumor +
BRCA2 is altered in 0.85% of gastrointestinal stromal tumor patients [3].
BRCA2 is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].
Fallopian Tube Transitional Cell Carcinoma +
BRCA2 is an inclusion criterion in 2 clinical trials for fallopian tube transitional cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and fallopian tube transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].
Ovarian Clear Cell Adenocarcinoma +
BRCA2 is an inclusion criterion in 2 clinical trials for ovarian clear cell adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Ovarian Transitional Cell Carcinoma +
BRCA2 is an inclusion criterion in 2 clinical trials for ovarian transitional cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and ovarian transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 2/phase 3 (1 open) [4].
Primary Peritoneal High Grade Serous Adenocarcinoma +
BRCA2 is an inclusion criterion in 2 clinical trials for primary peritoneal high grade serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].
Transitional Cell Carcinoma +
BRCA2 is altered in 8.2% of transitional cell carcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and transitional cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].
Endometrial Adenocarcinoma +
BRCA2 is altered in 8.78% of endometrial adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Ovarian Mucinous Adenocarcinoma +
BRCA2 is altered in 8.7% of ovarian mucinous adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for ovarian mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and ovarian mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Esophageal Squamous Cell Carcinoma +
BRCA2 is altered in 5.79% of esophageal squamous cell carcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Small Intestinal Neoplasm +
BRCA2 is altered in 11.06% of malignant small intestinal neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Carcinoma Of Unknown Primary +
BRCA2 is altered in 7.0% of carcinoma of unknown primary patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Uterine Neoplasm +
BRCA2 is altered in 7.76% of malignant uterine neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Intestinal Neoplasm +
BRCA2 is altered in 8.5% of malignant intestinal neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Colorectal Adenocarcinoma +
BRCA2 is altered in 8.37% of colorectal adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Neuroendocrine Carcinoma +
BRCA2 is altered in 5.96% of neuroendocrine carcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Gastric Neoplasm +
BRCA2 is altered in 6.33% of malignant gastric neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Malignant Ovarian Clear Cell Tumor +
BRCA2 is altered in 4.37% of malignant ovarian clear cell tumor patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant ovarian clear cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Ovarian Clear Cell Tumor +
BRCA2 is altered in 4.35% of ovarian clear cell tumor patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for ovarian clear cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and ovarian clear cell tumor as inclusion criteria, 1 is phase 3 (1 open) [4].
Malignant Esophagogastric Neoplasm +
BRCA2 is altered in 5.72% of malignant esophagogastric neoplasm patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +
BRCA2 is altered in 3.78% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Malignant Mixed Mesodermal (Mullerian) Tumor +
BRCA2 is altered in 5.15% of malignant mixed mesodermal (mullerian) tumor patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [4].
Biliary Tract Carcinoma +
BRCA2 is altered in 4.12% of biliary tract carcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ampulla Of Vater Carcinoma +
BRCA2 is altered in 4.43% of ampulla of vater carcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Bile Duct Adenocarcinoma +
BRCA2 is altered in 3.87% of bile duct adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].
Diffuse Large B-Cell Lymphoma +
BRCA2 is altered in 3.09% of diffuse large B-cell lymphoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].
Fallopian Tube Serous Adenocarcinoma +
BRCA2 is altered in 1.82% of fallopian tube serous adenocarcinoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
B-Cell Non-Hodgkin Lymphoma +
BRCA2 is altered in 2.43% of B-cell non-hodgkin lymphoma patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Malignant Ovarian Mixed Epithelial Tumor +
BRCA2 is altered in 2.94% of malignant ovarian mixed epithelial tumor patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for malignant ovarian mixed epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and malignant ovarian mixed epithelial tumor as inclusion criteria, 1 is phase 2/phase 3 (1 open) [4].
Langerhans Cell Histiocytosis +
BRCA2 is altered in 1.1% of langerhans cell histiocytosis patients [3].
BRCA2 is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].
Breast Fibrocystic Change, Proliferative Type +
BRCA2 is an inclusion criterion in 1 clinical trial for breast fibrocystic change, proliferative type, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and breast fibrocystic change, proliferative type as inclusion criteria, 1 is phase 2 (0 open) [4].
Breast Intraductal Proliferative Lesion +
BRCA2 is an inclusion criterion in 1 clinical trial for breast intraductal proliferative lesion, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and breast intraductal proliferative lesion as inclusion criteria, 1 is phase 2 (0 open) [4].
Bronchogenic Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Fallopian Tube Clear Cell Adenocarcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Fallopian Tube Mucinous Adenocarcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for fallopian tube mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and fallopian tube mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Fallopian Tube Undifferentiated Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for fallopian tube undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and fallopian tube undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Histiocytic Sarcoma +
BRCA2 is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Intraductal Proliferative Lesion Of The Breast +
BRCA2 is an inclusion criterion in 1 clinical trial for intraductal proliferative lesion of the breast, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and intraductal proliferative lesion of the breast as inclusion criteria, 1 is phase 2 (0 open) [4].
Juvenile Xanthogranuloma +
BRCA2 is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [4].
Low Grade Fallopian Tube Serous Adenocarcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for low grade fallopian tube serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and low grade fallopian tube serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Ovarian Endometrioid Adenocarcinofibroma +
BRCA2 is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinofibroma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and ovarian endometrioid adenocarcinofibroma as inclusion criteria, 1 is phase 3 (1 open) [4].
Peripheral Primitive Neuroectodermal Tumor +
BRCA2 is an inclusion criterion in 1 clinical trial for peripheral primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and peripheral primitive neuroectodermal tumor as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Clear Cell Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Low Grade Serous Adenocarcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for primary peritoneal low grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and primary peritoneal low grade serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Serous Papillary Adenocarcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for primary peritoneal serous papillary adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and primary peritoneal serous papillary adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Transitional Cell Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for primary peritoneal transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and primary peritoneal transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Primary Peritoneal Undifferentiated Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for primary peritoneal undifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and primary peritoneal undifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].
Vaginal Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
Vulvar Carcinoma +
BRCA2 is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA2 status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
